News

Civica Appoints Dave Sehgal as Chief Manufacturing Officer and Supply Chain Officer

Civica announced the appointment of Dave Sehgal, Ph.D. as its new Chief Manufacturing Officer and Supply Chain Officer, effective July 21. In this role, Dr. Sehgal will lead Civica’s manufacturing strategy and operations, reporting directly to Ned McCoy, President and CEO.

“We are excited to welcome Dave to our leadership team,” said McCoy. “His deep expertise in pharmaceutical manufacturing and global operations will be instrumental as we continue to bring our Petersburg facility online and expand access to essential medicines.”

Sehgal has nearly 30 years of experience in the pharmaceutical industry, having held leadership roles in the vaccines, biologics and small molecule manufacturing space. He also has significant experience in technical services, quality and process development. Dr. Sehgal succeeds Jay Benson.

“I am thrilled to join Civica at this time in the company’s history,” said Sehgal. “I look forward to leading the team that will bring high-quality, essential generic medicines, manufactured in the United Sates to patients who need them.”

Dr. Sehgal resides in Raleigh, NC and will be working closely with the Civica team at the company’s manufacturing facility in Petersburg, Va. The 140,000 square foot, state-of-the-art facility currently employs more than 200 skilled workers, with plans to hire another 60 employees by the end of 2025. The facility has the capacity to manufacture 90 million vials, 50 million syringes and 120 million pre-filled pens of generic sterile injectable medicines every year. The facility is in the final stages of certification by regulatory authorities and will be producing medicines for distribution in 2026.

Prior to joining Civica, Dr. Sehgal was the Vice President and Global Processing Engineering Head at CSL-Behring in Holly Springs, North Carolina. In that role, he led a team of 500 scientists and engineers across four global sites in support of all CSL-Behring products. Before CSL-Behring, Sehgal held leadership positions at FUJIFILM Diosynth Biotechnologies, Seqirus, Novartis, and Merck. Sehgal earned a bachelor’s, master’s, and doctoral degree in chemical engineering from NC State University.

This appointment reflects Civica’s continued commitment to operational excellence and its mission to make quality generic medicines accessible and affordable for all.

 

Read more here.

Recent News

10/27/2025

Virginia can lead biotech manufacturing renaissance – if policymakers help

Last week, pharmaceutical giant Merck broke ground on a new $3 billion facility in Virginia that will create 8,000 construction jobs and 500 permanent manufacturing jobs. The new 400,000 square-foot, state-of-the-art plant isn’t merely the latest addition to Virginia’s rapidly growing biotech industry footprint. It’s a sign that America is making quick progress towards President

10/22/2025

Virginia Catalyst Announces Round 19 of Grant Funding

The Virginia Catalyst announced today that it is accepting letters of intent (LOI) for Grant Round 19 to fund the development and commercialization of life science projects that address major unmet needs for improving human health and advance Virginia’s economy. “We at the Virginia Catalyst are pleased to provide funding in support of the Governor’s

10/21/2025

SRI multi-party team selected as an awardee by ARPA-H to develop at-home screening for ≥30 types of cancers

SRI, along with research partners Foothold Labs and Triple Ring Technologies and commercial partner Beacon Dx Health, has been awarded up to $34 million from the Advanced Research Projects Agency for Health (ARPA-H) to develop technology as part of the POSEIDON (Platform Optimizing SynBio for Early Intervention and Detection in Oncology) program. This pioneering program